Effect of prostatic apex shape (Lee types) and urethral sphincter length in preoperative MRI on very early continence rates after radical prostatectomy.


Journal

International urology and nephrology
ISSN: 1573-2584
Titre abrégé: Int Urol Nephrol
Pays: Netherlands
ID NLM: 0262521

Informations de publication

Date de publication:
Jul 2021
Historique:
received: 27 11 2020
accepted: 08 02 2021
pubmed: 20 2 2021
medline: 27 11 2021
entrez: 19 2 2021
Statut: ppublish

Résumé

To test the effect of anatomic variants of the prostatic apex overlapping the membranous urethra (Lee type classification), as well as median urethral sphincter length (USL) in preoperative multiparametric magnetic resonance imaging (mpMRI) on the very early continence in open (ORP) and robotic-assisted radical prostatectomy (RARP) patients. In 128 consecutive patients (01/2018-12/2019), USL and the prostatic apex classified according to Lee types A-D in mpMRI prior to ORP or RARP were retrospectively analyzed. Uni- and multivariable logistic regression models were used to identify anatomic characteristics for very early continence rates, defined as urine loss of ≤ 1 g in the PAD-test. Of 128 patients with mpMRI prior to surgery, 76 (59.4%) underwent RARP vs. 52 (40.6%) ORP. In total, median USL was 15, 15 and 10 mm in the sagittal, coronal and axial dimensions. After stratification according to very early continence in the PAD-test (≤ 1 g vs. > 1 g), continent patients had significantly more frequently Lee type D (71.4 vs. 54.4%) and C (14.3 vs. 7.6%, p = 0.03). In multivariable logistic regression models, the sagittal median USL (odds ratio [OR] 1.03) and Lee type C (OR: 7.0) and D (OR: 4.9) were independent predictors for achieving very early continence in the PAD-test. Patients' individual anatomical characteristics in mpMRI prior to radical prostatectomy can be used to predict very early continence. Lee type C and D suggest being the most favorable anatomical characteristics. Moreover, longer sagittal median USL in mpMRI seems to improve very early continence rates.

Identifiants

pubmed: 33606155
doi: 10.1007/s11255-021-02809-7
pii: 10.1007/s11255-021-02809-7
pmc: PMC8192356
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1297-1303

Références

Front Surg. 2019 Oct 25;6:60
pubmed: 31709260
Int Urol Nephrol. 2015 Aug;47(8):1343-9
pubmed: 26049974
J Urol. 2020 Jan;203(1):137-144
pubmed: 31347951
Eur Urol. 2016 Jan;69(1):41-9
pubmed: 26361169
Eur Urol. 2017 Mar;71(3):368-378
pubmed: 27394644
J Clin Nurs. 2014 Dec;23(23-24):3403-14
pubmed: 24890131
Eur Urol Focus. 2019 Sep;5(5):823-830
pubmed: 29759661
World J Urol. 2016 Jan;34(1):113-20
pubmed: 25991601
N Engl J Med. 2016 Oct 13;375(15):1425-1437
pubmed: 27626365
Urologe A. 2015 Jan;54(1):34-40
pubmed: 25214312
J Natl Compr Canc Netw. 2019 May 1;17(5):479-505
pubmed: 31085757
Prostate Int. 2020 Jun;8(2):55-61
pubmed: 32647641
Eur Urol Focus. 2021 Jan;7(1):95-101
pubmed: 30905598
Front Surg. 2020 Nov 10;7:584897
pubmed: 33240927
BJU Int. 2019 Jun;123(6):1031-1040
pubmed: 30927303
Eur Urol. 2012 Aug;62(2):333-40
pubmed: 22591631
Prostate Int. 2019 Jun;7(2):54-59
pubmed: 31384606
World J Urol. 2019 Jul;37(7):1289-1292
pubmed: 30993425
J Endourol. 2011 Jun;25(6):1025-30
pubmed: 21568755
Eur Urol. 2021 Jun;79(6):839-857
pubmed: 32536488
Urology. 2006 Jul;68(1):137-41
pubmed: 16777192
Eur Urol Focus. 2020 Sep 15;6(5):1013-1020
pubmed: 30691961
Eur Urol. 2019 Dec;76(6):814-822
pubmed: 30514568

Auteurs

Mike Wenzel (M)

Department of Urology, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany. Mike.Wenzel@kgu.de.
Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, QC, Canada. Mike.Wenzel@kgu.de.

Felix Preisser (F)

Department of Urology, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany.

Matthias Mueller (M)

Department of Urology, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany.

Lena H Theissen (LH)

Department of Urology, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany.

Maria N Welte (MN)

Department of Urology, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany.

Benedikt Hoeh (B)

Department of Urology, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany.

Clara Humke (C)

Department of Urology, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany.

Simon Bernatz (S)

Department of Diagnostic and Interventional Radiology, University Hospital Frankfurt, Frankfurt am Main, Germany.

Boris Bodelle (B)

Department of Diagnostic and Interventional Radiology, University Hospital Frankfurt, Frankfurt am Main, Germany.

Christoph Würnschimmel (C)

Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, QC, Canada.
Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany.

Derya Tilki (D)

Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany.

Hartwig Huland (H)

Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany.

Markus Graefen (M)

Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany.

Frederik C Roos (FC)

Department of Urology, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany.

Andreas Becker (A)

Department of Urology, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany.

Pierre I Karakiewicz (PI)

Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, QC, Canada.

Felix K H Chun (FKH)

Department of Urology, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany.

Luis A Kluth (LA)

Department of Urology, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany.

Philipp Mandel (P)

Department of Urology, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH